Related Experiment Videos
[Management of a patient receiving thalidomide]
Hélène Brocvielle1, Patrice Muret, Emmanuel Plenat
1Laboratoire d'ingénierie et de biologie cutanées, faculté de médecine et de pharmacie, Besançon.
Presse Medicale (Paris, France : 1983)
|January 10, 2004
Summary
Thalidomide, available under temporary marketing authorisation (TMA) in France, treats rare diseases like multiple myeloma. Strict surveillance is crucial due to severe side effects, including teratogenicity and neurotoxicity.
Area of Science:
- Pharmacology
- Oncology
- Immunology
Context:
- Thalidomide use in France is restricted to temporary marketing authorisation (TMA).
- Prescription and dispensing occur exclusively in hospital settings.
- It serves as a last-resort treatment for specific rare and severe conditions.
Purpose:
- To outline the current therapeutic landscape and indications for thalidomide in France.
- To highlight the critical need for rigorous patient surveillance due to thalidomide's side effect profile.
Summary:
- Thalidomide is indicated for lepromatous nodular erythema, severe aphthosis, Jessner-Kanoff's cutaneous lymphocyte infiltration, discoid lupus erythematosus, chronic graft-versus-host reactions, and refractory multiple myeloma.
- Disease recurrence often necessitates re-introduction of thalidomide after withdrawal.
- Potential for long-term, irreversible neurotoxicity and teratogenic effects mandates strict prescription and monitoring protocols.
Impact:
- Emphasizes the importance of comprehensive patient management strategies for thalidomide therapy.
- Underscores the necessity of efficient contraception and regular neurological assessments.
- Highlights the role of electroneurophysiological controls in mitigating risks associated with long-term thalidomide use.